Ian Read made chair of Pfizer in board reshuffle
This article was originally published in Scrip
Pfizer has elected its current president and CEO, Ian Read, chair of the board, succeeding George Lorch who has been named lead independent director. Pfizer has also elected Dr Marc Tessier-Lavigne and Dr Helen Hobbs to its board. Dr Tessier-Lavigne is president of The Rockefeller University, and previously served as executive vice-president of research and CSO at Genentech. Dr Hobbs is an investigator for the Howard Hughes Medical Institute and a professor of internal medicine and molecular genetics at the University of Texas Southwestern Medical Center. She is also a director of its McDermott Center for Human Growth and Development. Dr Michael Brown, a Pfizer director since 1996, has announced his intention to retire from the board in April 2012.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.